during the fast evolving industry of oncology research, exact and economical mutation screening is essential for building qualified therapies. The KRAS solutions Platform plays a pivotal job In this particular landscape by giving in depth methods for KRAS mutation profiling and Evaluation. KRAS mutations, found in around 95% of RAS-associated oncog